IP Library › Granted Patent US 8,329,714
Granted Patent B2
US 8,329,714 · App. 11/669,587 · Granted Dec 11, 2012

Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,329,714
App. No.
11/669,587
Granted
Dec 11, 2012
Kind
B2
Abstract

(−)-5-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts, and the use of such compounds in medicine especially for the treatment of cancer.

Claims (9)

1. A compound comprising: (−)-5-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine or a pharmaceutically acceptable acid addition salt thereof.

2. A compound comprising: (−)-5-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-tetrazolo[1,5-a]quinazoline-7-methanamine.

3. A pharmaceutical composition comprising the compound of claim 1 in a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising the compound of claim 2 in a pharmaceutically acceptable carrier.

5. A pharmaceutical composition of claim 3 in a dosage unit form.

6. The pharmaceutical composition of claim 5 comprising 50 to 300 mg of active ingredient in each unit dosage form.

7. The pharmaceutical composition of claim 6 in the form of a tablet.

8. A process for preparing a pharmaceutical composition as claimed in claim 3 wherein a therapeutically effective amount of the active ingredient is intimately mixed with a pharmaceutically acceptable carrier.

9. A process for the preparation of the compound of claim 1 which comprises treating (±)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine or a pharmaceutically acceptable acid addition salt thereof to separate the constituent (+) and (−) enantiomers and isolating the (−) enantiomer or a pharmaceutically acceptable acid addition salt thereof.